{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:01:07Z","timestamp":1786960867580,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010242","name":"Jiangsu Planned Projects for Postdoctoral Research Funds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20171121"],"award-info":[{"award-number":["BK20171121"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ando.2020.07.1113","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T11:13:21Z","timestamp":1597749201000},"page":"476-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor"],"prefix":"10.1016","volume":"81","author":[{"given":"Xiu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2020.07.1113_bib0145","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/dc19-S010","article-title":"Association, American, Cardiovascular disease and risk management: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2020.07.1113_bib0150","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.07.1113_bib0155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","article-title":"Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus","volume":"70","author":"Neumiller","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ando.2020.07.1113_bib0160","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2020.07.1113_bib0165","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.07.1113_bib0170","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/01.CIR.87.2.464","article-title":"Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure","volume":"87","author":"Yoshimura","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2020.07.1113_bib0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/332078a0","article-title":"A new natriuretic peptide in porcine brain","volume":"332","author":"Sudoh","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ando.2020.07.1113_bib0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2020.07.1113_bib0185","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00109-010-0641-2","article-title":"NPR-C: a component of the natriuretic peptide family with implications in human diseases S, Morriello A, et al","volume":"88","author":"Rubattu","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.ando.2020.07.1113_bib0190","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ando.2020.07.1113_bib0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy","volume":"19","author":"Diez","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ando.2020.07.1113_bib0200","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2337\/dc14-0669","article-title":"Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research","volume":"37","author":"Gruden","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2020.07.1113_bib0205","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0196-9781(97)00240-4","article-title":"Effect of atrial natriuretic peptide on sodium-glucose cotransport in the rat small intestine","volume":"18","author":"Gonzalez Bosc","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.ando.2020.07.1113_bib0210","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.07.1113_bib0215","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ndt\/gfu269","article-title":"Neprilysin inhibition in chronic kidney disease","volume":"30","author":"Judge","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ando.2020.07.1113_bib0220","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1373\/clinchem.2005.057638","article-title":"Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form","volume":"52","author":"Brandt","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2020.07.1113_bib0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yjmcc.2016.06.066","article-title":"A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II\/sodium-proton pump exchanger-1 axis","volume":"98","author":"Kawase","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ando.2020.07.1113_bib0230","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3389\/fimmu.2019.01050","article-title":"DPP-4 inhibitors as potential candidates for antihypertensive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ando.2020.07.1113_bib0235","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"Defronao RA.SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2020.07.1113_bib0240","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2020.07.1113_bib0245","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME Trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2020.07.1113_bib0250","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin's fuel hypothesis: not so soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ando.2020.07.1113_bib0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-017-3018-9","article-title":"Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?","volume":"433","author":"Shi","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.ando.2020.07.1113_bib0260","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.2337\/dc11-1959","article-title":"Prospective associations of B-type natriuretic peptidewith markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study","volume":"35","author":"Kroon","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2020.07.1113_bib0265","doi-asserted-by":"crossref","first-page":"e012797","DOI":"10.1161\/JAHA.119.012797","article-title":"Clinical and biomarker predictors of expanded heart failure outcomes in patients with type 2 diabetes mellitus after a recent acute coronary syndrome: insights from the EXAMINE trial","volume":"9","author":"Sharma","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ando.2020.07.1113_bib0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ejhf.1359","article-title":"The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes","volume":"21","author":"Rorth","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ando.2020.07.1113_bib0275","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00125-018-4727-7","article-title":"Prognostic value of plasma MR-proADM vs. NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study","volume":"61","author":"Fraty","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2020.07.1113_bib0280","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-5491.2009.02788.x","article-title":"N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients","volume":"26","author":"Cosson","year":"2009","journal-title":"Diabet Med"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620312063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620312063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:25:03Z","timestamp":1762086303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620312063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0003426620312063"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.07.1113","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.07.1113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}